Skip to main content
By Bryan Koenig (March 4, 2021 7:20 p.m. EST) – The Minnesota unit of Blue Cross and Blue Shield met Martin Shkreli on Thursday with what appears to be the first proposed private antitrust class action lawsuit against the jailed “pharma brother.” in the wake of a 2020 Federal Trade Commission case that made similar claims.

BCBSM Inc.’s lawsuit in New York federal court closely follows allegations by the FTC and seven attorneys general. It is seeking damages against Shkreli, his company Vyera Pharmaceuticals LLC – formerly Turing Pharmaceuticals – Vyera’s parent company, Phoenixus AG, and Phoenixus’ ex-Chairman Kevin Mulleady.

The insurer said Shkreli monopolized the market for the life-saving antiparasitic Daraprim…

Stay ahead of the curve

In the legal profession, information is the key to success. You need to know what’s happening with customers, competitors, operations, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data in articles (numbers, files, courts, type of action and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics, and more!

TRY LAW360 FOR FREE SEVEN DAYS